860 related articles for article (PubMed ID: 30121742)
1. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database.
Castillon G; Salvo F; Moride Y
Drug Saf; 2019 Jan; 42(1):27-34. PubMed ID: 30121742
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
3. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
[TBL] [Abstract][Full Text] [Related]
4. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
Ogar CK; Abiola A; Yuah D; Ibrahim A; Oreagba IA; Amadi EC; Adeyeye MC; Oshikoya KA
Pharmaceut Med; 2019 Apr; 33(2):145-157. PubMed ID: 31933250
[TBL] [Abstract][Full Text] [Related]
5. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
[TBL] [Abstract][Full Text] [Related]
6. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001).
Thiessard F; Roux E; Miremont-Salamé G; Fourrier-Réglat A; Haramburu F; Tubert-Bitter P; Bégaud B
Drug Saf; 2005; 28(8):731-40. PubMed ID: 16048358
[TBL] [Abstract][Full Text] [Related]
7. An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme.
Masuka JT; Khoza S
Pharmacol Res Perspect; 2020 Oct; 8(5):e00657. PubMed ID: 32930524
[TBL] [Abstract][Full Text] [Related]
8. Language does not come "in boxes": Assessing discrepancies between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese.
Inácio P; Airaksinen M; Cavaco A
Res Social Adm Pharm; 2015; 11(5):664-74. PubMed ID: 25596069
[TBL] [Abstract][Full Text] [Related]
9. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance.
Blake KV; Zaccaria C; Domergue F; La Mache E; Saint-Raymond A; Hidalgo-Simon A
Paediatr Drugs; 2014 Aug; 16(4):309-19. PubMed ID: 24898717
[TBL] [Abstract][Full Text] [Related]
10. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
[TBL] [Abstract][Full Text] [Related]
11. Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011.
Aagaard L; Hansen EH
Int J Clin Pharm; 2014 Dec; 36(6):1222-9. PubMed ID: 25288145
[TBL] [Abstract][Full Text] [Related]
12. Spontaneous adverse drug reaction reporting by patients in Canada: a multi-method study-study protocol.
Dweik RA; Yaya S; Stacey D; Kohen D
Springerplus; 2016; 5():213. PubMed ID: 27026907
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of paediatric studies of adverse drug reactions from pharmacovigilance databases.
Cliff-Eribo KO; Sammons H; Choonara I
Expert Opin Drug Saf; 2016 Oct; 15(10):1321-8. PubMed ID: 27501085
[TBL] [Abstract][Full Text] [Related]
14. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
[TBL] [Abstract][Full Text] [Related]
15. Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA.
Wu L; Ingle T; Liu Z; Zhao-Wong A; Harris S; Thakkar S; Zhou G; Yang J; Xu J; Mehta D; Ge W; Tong W; Fang H
BMC Bioinformatics; 2019 Mar; 20(Suppl 2):97. PubMed ID: 30871458
[TBL] [Abstract][Full Text] [Related]
16. Patient Reporting in the EU: Analysis of EudraVigilance Data.
Banovac M; Candore G; Slattery J; Houÿez F; Haerry D; Genov G; Arlett P
Drug Saf; 2017 Jul; 40(7):629-645. PubMed ID: 28417320
[TBL] [Abstract][Full Text] [Related]
17. Profile of adverse drug reaction reports in South Africa: An analysis of VigiBase® for the year 2017.
Steyn H
S Afr Med J; 2023 Jun; 113(6):26-33. PubMed ID: 37278262
[TBL] [Abstract][Full Text] [Related]
18. Rates of spontaneous reports of adverse drug reactions for drugs reported in children: a cross-sectional study with data from the Swedish adverse drug reaction database and the Swedish Prescribed Drug Register.
Wallerstedt SM; Brunlöf G; Sundström A
Drug Saf; 2011 Aug; 34(8):669-82. PubMed ID: 21751827
[TBL] [Abstract][Full Text] [Related]
19. Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden.
Holm L; Ekman E; Jorsäter Blomgren K
Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):335-343. PubMed ID: 28071845
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical adverse drug reactions: descriptive analysis of French reports.
Hakimi Y; Petitpain N; Pinzani V; Montastruc JL; Bagheri H
Eur J Clin Pharmacol; 2020 Aug; 76(8):1169-1174. PubMed ID: 32418024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]